{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:12:27Z","timestamp":1788642747042,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40123-026-01466-2","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:26:48Z","timestamp":1786447608000},"page":"3203-3219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-3263","authenticated-orcid":false,"given":"Imran","family":"Jawaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Lanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo-2024-325427","volume":"109","author":"J Liang","year":"2025","unstructured":"Liang J, et\u00a0al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109:362\u201371.","journal-title":"Br J Ophthalmol"},{"key":"1466_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, et\u00a0al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342.","journal-title":"Ophthalmology"},{"key":"1466_CR3","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, et\u00a0al. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61:49.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/bjo.85.5.521","volume":"85","author":"B Seet","year":"2001","unstructured":"Seet B. Myopia in Singapore: taking a public health approach. Br J Ophthalmol. 2001;85:521\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1466_CR5","unstructured":"Refractive Errors: Public Health Challenges and Interventions. https:\/\/www.frontiersin.org\/research-topics\/39154\/refractive-errors-public-health-challenges-and-interventions\/magazine."},{"key":"1466_CR6","unstructured":"Government instituted public health policy for myopia control in schools\u2014the overlooked variable in myopia prevention interventions? | Eye. https:\/\/www.nature.com\/articles\/s41433-024-03406-5."},{"key":"1466_CR7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.ophtha.2020.01.054","volume":"127","author":"P-C Wu","year":"2020","unstructured":"Wu P-C, et\u00a0al. Increased time outdoors is followed by reversal of the long-term trend to reduced visual acuity in Taiwan primary school students. Ophthalmology. 2020;127:1462\u20139.","journal-title":"Ophthalmology"},{"key":"1466_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","volume":"140","author":"J Bao","year":"2022","unstructured":"Bao J, et\u00a0al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA Ophthalmol. 2022;140:472\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1466_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","volume":"131","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, et\u00a0al. Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report. Ophthalmology. 2024;131:1011\u201320.","journal-title":"Ophthalmology"},{"key":"1466_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/aos.14911","volume":"100","author":"TM Jakobsen","year":"2022","unstructured":"Jakobsen TM, M\u00f8ller F. Control of myopia using orthokeratology lenses in Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish randomized study: clinical study of near-sightedness; treatment WITH orthokeratology lenses (CONTROL study). Acta Ophthalmol (Copenh). 2022;100:175\u201382.","journal-title":"Acta Ophthalmol. (Copenh.)"},{"key":"1466_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1136\/bjo-2021-321005","volume":"107","author":"J Rappon","year":"2023","unstructured":"Rappon J, et\u00a0al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023;107:1709\u201315.","journal-title":"Br J Ophthalmol"},{"key":"1466_CR12","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, et\u00a0al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391.","journal-title":"Ophthalmology"},{"key":"1466_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","volume":"96","author":"P Chamberlain","year":"2019","unstructured":"Chamberlain P, et\u00a0al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96:556\u201367.","journal-title":"Optom Vis Sci"},{"key":"1466_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32700-7","volume":"13","author":"CSY Lam","year":"2023","unstructured":"Lam CSY, et\u00a0al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13:5475.","journal-title":"Sci Rep"},{"key":"1466_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40662-025-00427-3","volume":"12","author":"X Li","year":"2025","unstructured":"Li X, et\u00a0al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis Lond Engl. 2025;12:10.","journal-title":"Eye Vis Lond Engl"},{"key":"1466_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JWL Tideman","year":"2016","unstructured":"Tideman JWL, et\u00a0al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355\u201363.","journal-title":"JAMA Ophthalmol"},{"key":"1466_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu Q-S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2. Ophthalmology. 2016;123:391\u20139.","journal-title":"Ophthalmology"},{"key":"1466_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, et\u00a0al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354.","journal-title":"Ophthalmology"},{"key":"1466_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, et\u00a0al. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157:451-457.e1.","journal-title":"Am J Ophthalmol"},{"key":"1466_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, et\u00a0al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology. 2020;127:910\u20139.","journal-title":"Ophthalmology"},{"key":"1466_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, et\u00a0al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308\u201321.","journal-title":"Ophthalmology"},{"key":"1466_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/OPX.0000000000002176","volume":"101","author":"NA Brennan","year":"2024","unstructured":"Brennan NA, Shamp W, Maynes E, Cheng X, Bullimore MA. Influence of age and race on axial elongation in myopic children: a systematic review and meta-regression. Optom Vis Sci. 2024;101:497\u2013507.","journal-title":"Optom Vis Sci"},{"key":"1466_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/opo.13401","volume":"45","author":"T Naduvilath","year":"2025","unstructured":"Naduvilath T, et\u00a0al. Regional\/ethnic differences in ocular axial elongation and refractive error progression in myopic and non-myopic children. Ophthalmic Physiol Opt. 2025;45:135\u201351.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1466_CR24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, et\u00a0al. Efficacy and safety of 0.01% and 0.02% Atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","volume":"2","author":"S McCrann","year":"2019","unstructured":"McCrann S, et\u00a0al. Myopia outcome study of Atropine in children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Res. 2019;2:15.","journal-title":"HRB Open Res"},{"key":"1466_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, et\u00a0al. Low-dose 0.01% Atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365.","journal-title":"JAMA Ophthalmol."},{"key":"1466_CR27","first-page":"02","volume":"02","author":"R Saxena","year":"2021","unstructured":"Saxena R, et\u00a0al. Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial. Ophthalmology. 2021;02:02.","journal-title":"Ophthalmology"},{"key":"1466_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/ceo.14368","volume":"52","author":"SSY Lee","year":"2024","unstructured":"Lee SSY, et\u00a0al. Myopia progression following 0.01% atropine cessation in Australian children: findings from the Western Australia - Atropine for the treatment of Myopia (WA-ATOM) study. Clin Experiment Ophthalmol. 2024;52:507\u201315.","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"1466_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/opo.13195","volume":"43","author":"FS Yii","year":"2023","unstructured":"Yii FS. Emmetropic eye growth in East Asians and non-East Asians. Ophthalmic Physiol Opt. 2023;43:1412\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1466_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01341-0","author":"M Korenfeld","year":"2026","unstructured":"Korenfeld M, et\u00a0al. Study of Atropine to Reduce (STAR) myopia progression in children: 24-month results of a randomized double-masked vehicle-controlled trial of atropine sulfate 0.01% and 0.03%. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01341-0.","journal-title":"Ophthalmol Ther"},{"key":"1466_CR31","unstructured":"Corneal Penetration of Low-Dose Atropine Eye Drops - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33557281\/."},{"key":"1466_CR32","unstructured":"Deuterium in drug discovery: progress, opportunities and challenges | Nature Reviews Drug Discovery. https:\/\/www.nature.com\/articles\/s41573-023-00703-8."},{"key":"1466_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s44402-026-00064-w","author":"K Zadnik","year":"2026","unstructured":"Zadnik K, et\u00a0al. Negligible rebound in myopia progression following cessation of treatment with 0.01% atropine for 3 years: year-4 results from the CHAMP Phase 3 clinical trial. Ophthalmic Physiol Opt. 2026. https:\/\/doi.org\/10.1007\/s44402-026-00064-w.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1466_CR34","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, et\u00a0al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol (Copenh). 2024;102:e245\u201356.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"1466_CR35","first-page":"427","volume":"65","author":"J Loughman","year":"2024","unstructured":"Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft I. The MOSAIC study: year 3 results of 0.01% and 0.05% atropine treatment in a European population. Invest Ophthalmol Vis Sci. 2024;65:427.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1466_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamaophthalmol.2024.5703","volume":"143","author":"J Loughman","year":"2025","unstructured":"Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI. Efficacy and safety of different atropine regimens for the treatment of myopia in children: three-year results of the MOSAIC randomized clinical trial. JAMA Ophthalmol. 2025;143:134\u201344.","journal-title":"JAMA Ophthalmol"},{"key":"1466_CR37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS-Y Lee","year":"2022","unstructured":"Lee SS-Y, et\u00a0al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Experiment Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Experiment Ophthalmol"},{"key":"1466_CR38","first-page":"175","volume":"14","author":"NC Hansen","year":"2024","unstructured":"Hansen NC, et\u00a0al. Two-year results of 0.01% Atropine eye drops and 0.1% loading dose for myopia progression reduction in Danish children: a placebo-controlled. Randomized Clin Trial J Pers Med. 2024;14:175.","journal-title":"Randomized Clin Trial J Pers Med."},{"key":"1466_CR39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/bjo-2024-326918","volume":"109","author":"N Hansen","year":"2025","unstructured":"Hansen N, et\u00a0al. 3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial. Br J Ophthalmol. 2025;109:1056\u201363.","journal-title":"Br. J. Ophthalmol."},{"key":"1466_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12886-023-03177-9","volume":"23","author":"NC Hansen","year":"2023","unstructured":"Hansen NC, et\u00a0al. Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety. BMC Ophthalmol. 2023;23:438.","journal-title":"BMC Ophthalmol."},{"key":"1466_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189774","volume":"12","author":"R Saxena","year":"2017","unstructured":"Saxena R, et\u00a0al. Incidence and progression of myopia and associated factors in urban school children in Delhi: the North India Myopia Study (NIM Study). PLoS ONE. 2017;12:e0189774.","journal-title":"PLoS ONE"},{"key":"1466_CR42","doi-asserted-by":"crossref","unstructured":"Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study. Asia-Pac. J. Ophthalmol. 12, 370\u2013376 (2023).","DOI":"10.1097\/APO.0000000000000609"},{"key":"1466_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100960","author":"K Ohno-Matsui","year":"2026","unstructured":"Ohno-Matsui K, Igarashi-Yokoi T, Migita Y, Yamakawa Y. Efficacy and safety of low-concentration atropine in slowing myopia progression in children in Japan: the randomized, double-blind phase II\/III ORANGE study. Ophthalmol Sci. 2026. https:\/\/doi.org\/10.1016\/j.xops.2025.100960.","journal-title":"Ophthalmol Sci"},{"key":"1466_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/cxo.12967","volume":"103","author":"S Khanal","year":"2020","unstructured":"Khanal S, Phillips JR. Which low\u2010dose atropine for myopia control? Clin Exp Optom. 2020;103:230\u20132.","journal-title":"Clin Exp Optom"},{"key":"1466_CR45","doi-asserted-by":"publisher","first-page":"1497667","DOI":"10.3389\/fphar.2025.1497667","volume":"16","author":"P Navarra","year":"2025","unstructured":"Navarra P, Buzzonetti L, Amico V, Cro M, Federico B. A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children\u2019s populations. Front Pharmacol. 2025;16:1497667.","journal-title":"Front. Pharmacol"},{"key":"1466_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2025-328942","author":"XJ Zhang","year":"2026","unstructured":"Zhang XJ, et\u00a0al. Efficacy of 0.01% atropine eye drops for myopia control in children of different ethnicities: a systematic review and meta-analysis. Br J Ophthalmol. 2026. https:\/\/doi.org\/10.1136\/bjo-2025-328942.","journal-title":"Br. J. Ophthalmol."},{"key":"1466_CR47","volume":"14","author":"AR Cyril Kurupp","year":"2022","unstructured":"Cyril Kurupp AR, et\u00a0al. The impact of the COVID-19 pandemic on myopia progression in children: a systematic review. Cureus. 2022;14:e28444.","journal-title":"Cureus"},{"key":"1466_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/opo.13403","volume":"45","author":"MA Bullimore","year":"2025","unstructured":"Bullimore MA, Brennan NA. Efficacy in myopia control-the impact of rebound. Ophthalmic Physiol Opt. 2025;45:100\u201310.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1466_CR49","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaophthalmol.2026.0436","volume":"144","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, et\u00a0al. Discontinuation approach and follow-up of low-concentration Atropine for Myopia progression: eight-year results of the LAMP randomized clinical trial. JAMA Ophthalmol. 2026;144:396\u2013403.","journal-title":"JAMA Ophthalmol"},{"key":"1466_CR50","doi-asserted-by":"publisher","unstructured":"Myopia management in the Netherlands - CW Klaver - 2020 - Ophthalmic and Physiological Optics - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/opo.12676.","DOI":"10.1111\/opo.12676"},{"key":"1466_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100753","volume":"5","author":"BX Sim","year":"2025","unstructured":"Sim BX, et\u00a0al. Additive effect of highly aspherical lenslet target spectacles to children inadequately controlled by atropine monotherapy. Ophthalmol Sci. 2025;5:100753.","journal-title":"Ophthalmol Sci"},{"key":"1466_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25599-z","volume":"12","author":"Z Huang","year":"2022","unstructured":"Huang Z, Chen X-F, He T, Tang Y, Du C-X. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12:22311.","journal-title":"Sci Rep"},{"key":"1466_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281816","volume":"18","author":"P Nucci","year":"2023","unstructured":"Nucci P, et\u00a0al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine. PLoS ONE. 2023;18:e0281816.","journal-title":"PLoS ONE"},{"key":"1466_CR54","unstructured":"Beta and gamma peripapillary atrophy in myopic eyes with and without glaucoma | IOVS | ARVO Journals. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2529057."},{"key":"1466_CR55","unstructured":"Clinical features of microvasculature in subzones of parapapillary atrophy in myopic eyes: an OCT-angiography study | Eye. https:\/\/www.nature.com\/articles\/s41433-020-0872-6."},{"key":"1466_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ajo.2024.10.003","volume":"270","author":"Z Pan","year":"2025","unstructured":"Pan Z, et\u00a0al. Prevalence, features, and risk factors of macular retinoschisis in high myopic population: the Beijing eye study 2011. Am J Ophthalmol. 2025;270:227\u201336.","journal-title":"Am J Ophthalmol"},{"key":"1466_CR57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/iovs.65.10.43","volume":"65","author":"C Li","year":"2024","unstructured":"Li C, et\u00a0al. Long-term prediction and risk factors for incident visual field defect in nonpathologic high myopia. Invest Ophthalmol Vis Sci. 2024;65:43.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1466_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101085","author":"XJ Zhang","year":"2026","unstructured":"Zhang XJ, et\u00a0al. Effect of low-concentration atropine eyedrops on parapapillary gamma zone development and enlargement over 3 years: the LAMP1 study. Ophthalmol Sci. 2026. https:\/\/doi.org\/10.1016\/j.xops.2026.101085.","journal-title":"Ophthalmol. Sci."},{"key":"1466_CR59","volume":"17","author":"S Parida","year":"2025","unstructured":"Parida S, et\u00a0al. Effect of low-dose atropine on choroidal thickness in children with myopia progression. Cureus. 2025;17:e88047.","journal-title":"Cureus"},{"key":"1466_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1440180","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wei L, Wang B, Zheng W. Effects of atropine on choroidal thickness in myopic children: a meta-analysis. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1440180.","journal-title":"Front Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01488-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01466-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01466-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01466-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:02:52Z","timestamp":1788642172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01466-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01466-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to incorrect value 0.02% in Methods, sub-section STAR and incorrect figure 2 caption. Now, it have been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01488-w","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01488-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carla Lanca reports a consulting or advisory relationship with Eyerising and has had accommodation expenses covered by EssilorLuxottica in connection with conference attendance, research meetings, or presentations. Carla Lanca is an editorial board member of\n                      Ophthalmology and Therapy\n                      . Carla Lanca was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Imran Jawaid has a consulting or advisory relationship with Santen pharmaceuticals.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}